Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

STLN vs SABS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SABS Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 7–1 Matrix Metrics)

SABS Overall Winner 6-Pillar Tally: STLN 0 – 4 SABS (2 Tie) Matrix Metrics: STLN 1 – 7 SABS

As of Nov 20, 2026, SAB Biotherapeutics, Inc. (SABS) is the stronger overall head-to-head candidate over STLN (STLN) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). STLN carries a Unified Composite Score of 46.6/100 (HOLD) at $3.00 (N/M Forward P/E, N/A operating margin), whereas SABS carries 37.4/100 (SELL) at $2.81 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While STLN currently prints a higher short-term Unified Composite Score (46.6/100 HOLD vs. SABS 37.4/100 SELL), SABS captures the overall institutional head-to-head verdict (7–1 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (-62.4% vs. N/A YoY).
  • Technical & Structure Timing Caution: STLN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.4); meanwhile SABS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About STLN vs SABS
STLN US Equity
STLN
Institutional Equity
$3.00
-5.66% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.42β · 175% Vol
Unified Composite Score
46.6 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.2%), weak momentum, RSI 26
RSI-14: 26.4 · SMA20: $4.93 · SMA50: $5.93
SABS NASDAQ Head-to-Head Winner
SAB Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$2.81
-3.44% 1D
Market Cap $262.2M
TTM Revenue $114,698
Forward P/E N/M
Beta / 30D Vol 1.38β · 76% Vol
Unified Composite Score
37.4 / 100 SELL
Tech 20.0 Fund 52.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 43
RSI-14: 42.7 · SMA20: $3.07 · SMA50: $3.07

6-Pillar Scorecard Institutional Category Breakdown (STLN 0 – 4 SABS)

Columns: Metric · STLN · SABS
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale SABS
Revenue Growth (YoY) N/A -62.4%
Earnings Growth (YoY) N/A -60.0%
TTM Revenue (USD) N/A $114,698
Market Cap N/A $262.2M
3. Profitability & Quality SABS
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -42.8%
4. Balance Sheet & Cash Flow SABS
Cash Generation (TTM) N/A -$59M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $9.5M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SABS
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 124.0% (21st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: STLN (1) vs SABS (7)
Institutional Metric STLN SABS Criterion Row Edge
Market Capitalization
Scale
N/A $262.2M Larger Scale SABS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -62.4% Higher Growth SABS
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin SABS
Net Profit Margin
Profitability
N/A 0.0% Higher Margin SABS
Return on Equity (ROE)
Capital Efficiency
N/A -42.8% Higher ROE SABS
52-Week Range Position
Momentum
1% ($3–$7) 14% ($2–$5) Stronger Trend SABS
Beta / 30D Volatility
Risk Regime
1.42β · 175% Vol 1.38β · 76% Vol Lower Realized Risk SABS
Unified Institutional Score
Composite Signal
46.6 / 100 (HOLD) 37.4 / 100 (SELL) Higher Composite STLN
Trailing 12M Revenue (USD)
Operating Scale
N/A $114,698 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$59M ($9.5M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SABS +49.01 pp
STLN: -56.58% · SABS: -7.57%
3M Horizon SABS +28.68 pp
STLN: -51.06% · SABS: -22.38%
6M Horizon SABS +14.96 pp
STLN: -41.97% · SABS: -27.01%
1Y Horizon SABS +14.96 pp
STLN: -41.97% · SABS: -27.01%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on STLN vs SABS. Trailing 12-month operating profitability (STLN N/A vs SABS 0.0%) and valuation multiples (STLN N/M vs SABS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

STLN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
SABS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$114,698
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-42.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
STLN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact STLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SABS CONSOLIDATION
15d in phase · OBV DISTRIBUTION
Current IV 124.0%
IV Percentile 21st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SABS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
STLN Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SABS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $262.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ STLN vs SABS Key Questions & Quantitative Answers

As of Nov 20, 2026, SAB Biotherapeutics, Inc. (SABS) is the stronger overall head-to-head candidate over STLN (STLN) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). STLN carries a Unified Composite Score of 46.6/100 (HOLD) at $3.00 (N/M Forward P/E, N/A operating margin), whereas SABS carries 37.4/100 (SELL) at $2.81 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While STLN currently prints a higher short-term Unified Composite Score (46.6/100 HOLD vs. SABS 37.4/100 SELL), SABS captures the overall institutional head-to-head verdict (7–1 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (-62.4% vs. N/A YoY). Technical & Structure Timing Caution: STLN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.4); meanwhile SABS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SABS leads the Growth & Scale pillar: STLN posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SABS at -62.4% YoY revenue growth and -60.0% YoY earnings growth on $114,698 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, STLN generates N/A in USD-normalized revenue versus $114,698 for SABS. In operating R&D and SG&A reinvestment, STLN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SABS.

STLN and SABS trade at balanced relative valuation multiples. STLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SABS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against STLN (N/A ROE) versus SABS (-42.8% ROE) capital efficiency.

In options market volatility and institutional positioning, STLN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.42β · 175% Vol realized risk). By comparison, SABS carries 124.0% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.38β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.